Contents

Search

zolbetuximab-clzb

Indications: - incombination with with fluoropyrimidine- & platinum-containing chemotherapy, for first-line treatment locally advanced unresectable or metastatic HER2-negative CLDN18.2 positive, gastric or gastroesophageal junction adenocarcinoma Dosage: - First dose: 800 mg/m2 intravenously - Subsequent dosage: - 600 mg/m2 intravenously every 3 weeks, or - 400 mg/m2 intravenously every 2 weeks Adverse effects: - vomiting, nausea, diarrhea, intestinal obstruction - neutropenia, febrile neutropenia, pyrexia, sepsis - pneumonia, respiratory failure, pulmonary embolism Mechanism of action: - claudin 18.2 (CLDN18.2)-directed cytolytic antibody

Interactions

drug adverse effects of pharmaceutical monoclonal antibodies

General

antineoplastic monoclonal antibody

References

  1. FDA-approval Oct 18, 2023 FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zolbetuximab-clzb-chemotherapy-gastric-or-gastroesophageal-junction-adenocarcinoma